简易混悬法鼻胃管给药对替拉鲁替尼血清浓度的影响:一例病例报告
本文报告一例82岁复发原发性中枢神经系统淋巴瘤男性患者,替拉鲁替尼320 mg/日空腹口服因吞咽困难改为简易混悬法鼻胃管给药后,给药后11小时血清浓度由83.2 ng/mL升至191 ng/mL,增幅超过2倍。作者提示鼻胃管给药可能升高替拉鲁替尼浓度,需加强临床监测并考虑治疗药物监测。
要点
- 鼻胃管简易混悬法给药后替拉鲁替尼血清浓度较口服升高超过2倍。
- 浓度升高可能主要反映简易混悬法改善药物分散与吸收。
- 无法口服片剂的患者应加强临床监测,必要时考虑治疗药物监测。
核心结论
- 替拉鲁替尼经简易混悬法鼻胃管给药后血清浓度可能升高。
- 无法口服片剂的患者需仔细临床监测,特定病例可考虑治疗药物监测。
研究设计与样本
- 单例病例报告:82岁男性复发原发性中枢神经系统淋巴瘤患者。
- 替拉鲁替尼320 mg/日空腹给药,比较口服与简易混悬法鼻胃管给药后11小时血清浓度。
主要发现
- 给药后11小时血清替拉鲁替尼浓度由口服83.2 ng/mL升至鼻胃管给药191 ng/mL,增幅超过2倍。
- 两次给药剂量、合并用药及采样条件一致。
- 第19天出现疑似药物性皮疹并停用替拉鲁替尼,但鼻胃管给药浓度未明显高于既往报告的平均12小时浓度约120 ng/mL。
关键数值与推荐
- 口服给药后11小时血清替拉鲁替尼浓度为83.2 ng/mL。
- 简易混悬法鼻胃管给药后11小时血清替拉鲁替尼浓度为191 ng/mL。
- 既往报告的平均12小时血清浓度约为120 ng/mL。
临床怎么用
- 无法吞咽片剂而采用简易混悬法鼻胃管给药时,应警惕替拉鲁替尼暴露升高。
- 对此类患者应加强临床监测,特定病例可考虑治疗药物监测。
局限性
- 单例病例报告,结果不能外推至所有患者。
- 不能排除吸收速率变化或个体间变异等辅助因素。
- 需积累更多病例及药代动力学研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Tirabrutinib, an oral Bruton's tyrosine kinase inhibitor, is used in the treatment of relapsed or refractory primary central nervous system lymphoma (PCNSL) and other B cell malignancies. Although this medication is also administered to older patients, those experiencing dysphagia may require nasogastric administration via a tube. The impact of different administration routes on pharmacokinetics remains a pertinent clinical concern. SUMMARY: An 82-year-old male patient with relapsed PCNSL initiated tirabrutinib at 320 mg/day under fasting conditions. While the patient was initially able to swallow tablets, progression of dysphagia necessitated a switch to nasogastric administration using the simple suspension method. Serum tirabrutinib concentrations were determined 11 hours after administration by each route using liquid chromatography followed by tandem mass spectrometry and compared. The serum concentration increased from 83.2 ng/mL with oral administration to 191 ng/mL with nasogastric administration, representing an increase of more than 2-fold. The dose, concomitant medications, and sampling conditions were consistent. On day 19, a rash developed that was suspected to be drug induced, prompting discontinuation of tirabrutinib; however, the serum concentration with nasogastric administration was not markedly higher than the previously reported mean 12-hour concentration of around 120 ng/mL. The observed increase in tirabrutinib concentration may primarily reflect enhanced dispersion with the simple suspension method, leading to improved absorption. Potential auxiliary factors, such as changes in absorption rate or inter-individual variability, cannot be excluded. Although a rash occurred, it is unlikely to represent an adverse event due to excessive exposure. CONCLUSION: Tirabrutinib concentrations may increase with nasogastric administration using the simple suspension method. In patients unable to ingest tablets orally, careful clinical monitoring is warranted, and therapeutic drug monitoring may be considered in select cases. The accumulation of further cases and pharmacokinetic investigations are warranted.
引用
- Yashima H, Araki T, Kaneta A, et al. Impact of nasogastric administration using the simple suspension method on serum tirabrutinib levels: A case report. Am J Health Syst Pharm. 2026. PMID: 42317146. doi:10.1093/ajhp/zxag190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。